The REMoDL-A clinical trial evaluates the addition of acalabrutinib to standard of care therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients with previously untreated CD20 positive Diffuse Large B-Cell Lymphoma (DLBCL). As part of the study, original diagnostic FFPE tumour blocks are collected for gene expression profiling and central pathology review using IHC and FISH analysis. Tissue microarray blocks may also be produced if there is sufficient tissue left in the diagnostic FFPE tumour block. ETDA blood samples are collected at baseline before administration of any study drugs and ctDNA blood samples are also collected at 8 different timepoints throughout the study (at baseline, during trial treatment and during follow-up).

ELECTRA is a feasibility trial to determine whether it is acceptable and feasible to recruit, randomise and deliver Intraoperative Electron Radiotherapy (IOERT) in a randomised controlled trial setting. Patients with locally advanced rectal cancer or locally recurrent rectal cancer involving the pelvic sidewall or posterior bony pelvis will be randomised to receive either extended margin surgery along, extended margin surgery with IOERT at standard dose (10 Gy), or extended margin surgery with IOERT at higher dose (15 Gy). Patients will be randomised to the three treatment arms in a 1:1:1 ratio. Patients will be followed up for a minimum of 12 months and up to 24 months following their surgery.

A randomised phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer

A phase 1b TiTE-CRM dose escalation clinical trial of tolinapant (ASTX660) in combination with standard radical chemoradiotherapy in cervical cancer.

A phase I/II trial to determine if the addition of the AKT inhibitor AZD5363 to docetaxel and prednisolone (DP) prolongs progression free survival (PFS) in metastatic castration resistant prostate cancer (mCRPC) to a degree worthy of further investigation.

SGI-110 is a DNA methyltransferase inhibitor developed for optimised delivery of the active metabolite decitabine. Pre-clinical data support that cisplatin resistance in bladder and other cancers is derived, at least in part, through promotor methylation of silenced genes relevant to a cisplatin resistance phenotype. Experimentally this is reversible through co-administration of DNA hypomethylating agents. The central hypothesis to be tested in this clinical trial is that SGI-110 can be safely combined with GC in bladder cancer at doses able to induce demethylation of genes associated with cisplatin resistance.

tissue specimen, serum, plasma,

A Phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patient with Diffuse Large B-cell Lymphoma

A Phase IIa study of Rituximab and Varlilumab in relapsed or refractory B-cell malignancies

An international phase II trial assessing tolerability and efficacy of sequential Methotrexate-Aracytin-based combination and R-ICE combination, followed by high-dose chemotherapy supported by autologous stem cell transplant, in patients with systemic B-cell lymphoma with central nervous system involvement at diagnosis or relapse (MARIETTA regimen). This is an open, non comparative, multicentre phase II trial, to evaluate the efficacy and feasibility of a new sequential combination of HD-MTX-AraC-based chemoimmunotherapy, followed by R-ICE regimen, and by high-dose chemotherapy supported by ASCT.